VOGX — Vogenx, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1903784 ·
Last close
$11.87
Market Cap
$176.33M
52W High
$38.41
52W Low
$11.51
ADV30
107,064
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -1,782,736 | -4,907,603 | 82,843,273 | 5,126,137 | 842,470 |
| Jun 2026 | 0 | — | -355,384 | -384,430 | 1,409,028 | 193,017 | 3,188,329 |
| Mar 2026 | 0 | — | -463,153 | -475,452 | 898,459 | 250,753 | 2,297,998 |
| Dec 2025 | 0 | — | -453,783 | -509,780 | 681,170 | 601,010 | 1,600,405 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-895,766
Investing CF
—
Financing CF
—
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.11
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-11,701,552
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-1,501,395
Pretax Income TTM
$-1,511,298
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,439,118 | -1,445,603 | 681,170 | 1,600,405 | -919,235 | -1,111,913 |
| Dec 2024 | 0 | -2,300,834 | -2,203,591 | 970,398 | 460,814 | 509,584 | -2,341,372 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$1,409,028
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NATR | NATURES SUNSHINE PRODUCTS INC | $176.41M | $10.18 | — |
| ADCT | ADC Therapeutics SA | $180.05M | $1.28 | — |
| SIGA | SIGA TECHNOLOGIES INC | $172.45M | $2.40 | — |
| SLGL | Sol-Gel Technologies Ltd. | $180.63M | $55.17 | — |
| WHWK | Whitehawk Therapeutics, Inc. | $181.16M | $3.07 | — |
News headlines (Yahoo Finance, 1h cache)
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
2026-11-19 13:30 · Yahoo
Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-06 11:30 · Yahoo
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
2026-10-15 20:35 · Yahoo
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
2026-10-09 12:00 · Yahoo
Vogenx Appoints Ken Toombs to Board of Directors
2026-09-22 13:00 · Yahoo
Federal Filings Joins Client Vogenx at the Nasdaq Opening Bell
2026-08-24 23:00 · Yahoo
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
2026-08-17 16:25 · Yahoo
Vogenx Announces Closing of Initial Public Offering
2026-08-13 20:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.